Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ

Kawaljit Kaur; Yujie Sun; Keiichi Kanayama; Kenzo Morinaga; Akishige Hokugo; Ichiro Nishimura; Anahid Jewett

doi:10.3389/fendo.2023.1111627

. 2023 Jan 20;14:1111627. doi: 10.3389/fendo.2023.1111627

Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ

Kawaljit Kaur ^1,², Yujie Sun ^1,³, Keiichi Kanayama ^1,^3,⁴, Kenzo Morinaga ^1,^3,⁵, Akishige Hokugo ^1,⁶, Ichiro Nishimura ^1,^2,^3,^*, Anahid Jewett ^1,^2,^*

PMCID: PMC9895394 PMID: 36742414

Abstract

Introduction

The potential mechanisms governing drug induced osteonecrosis of the jaw (ONJ) is not well understood, and is one of the objectives of this study. Thus, we tested the release of IFN-γ within different immune compartments including bone marrow and gingivae upon treatment with zoledronic acid (ZOL) and denosumab which are known to induce ONJ in susceptible individuals.

Methods

We used humanized-BLT mouse model for the in-vivo studies reported in this paper. To determine the effects of zoledronic acid and denosumab on IFN-γ secretion and NK cell-mediated cytotoxicity; peripheral blood, bone marrow, spleen and gingiva were obtained after the injection of ZOL and denosumab in mice.

Results

Percentages of B cells are much higher in wild-type mice whereas the proportions of immune subsets in humans and reconstituted hu-BLT peripheral-blood are similar. Therefore, hu-BLT mice are preferable model to study human disease, in particular, immune-pathologies induced by ZOL and denosumab. Both agents resulted in a severe suppression of IFN-γ in the gingiva, whereas they heightened the release of IFN-γ and NK cell-mediated cytotoxicity by the BM-derived immune cells. ZOL increased the IFN-γ secretion by the spleen and peripheral blood immune cells, whereas denosumab decreased the release IFN-γ by these cells significantly.

Discussion

ZOL and denosumab may likely suppress IFN-γ secretion in gingiva through different mechanisms. In addition, to the suppression of IFN-γ secretion, denosumab mediated effect could in part be due to the decrease in the bone resorptive function of osteoclasts due to the induction of antibody dependent cellular cytotoxicity and lysis of osteoclasts, whereas ZOL is able to mediate cell death of osteoclasts directly. Suppression of IFN-gamma in gingiva is largely responsible for the inhibition of immune cell function, leading to dysregulated osteoblastic and osteoclastic activities. Restoration of IFN-gamma in the local microenvironment may result in establishment of homeostatic balance in the gingiva and prevention of osteonecrosis of jaw.

Keywords: zoledronic acid, denosumab, osteonecrosis of the jaw, NK cells, antibody-dependent cellular cytotoxicity (ADCC), humanized-BLT mice, cytotoxicity, IFN-γ

Introduction

Bisphosphonates (BPs) are the prototypic anti-resorptive medication (1). Osteonecrosis of the jaw (ONJ), also known as BP-related ONJ (BRONJ) occurs in patients treated with BPs, mostly in the segment of jawbone interfacing oral mucosa (2). The overall prevalence of BRONJ is relatively low and an overwhelming proportion of the reported cases are related to high-dose intravenous BPs in cancer patients with multiple myeloma (55.9%) and breast cancer (33.4%) (3–5). BRONJ was first described in early 2000’s (6–8); however, the pathological mechanism and therapeutic modalities have not yet been established. Tooth extraction (9, 10), periodontitis (11) and, ill-fitting dentures (12) were reported to increase the risk of ONJ.

Oral mucosa and gingiva, which overlays the alveolar bone of the maxilla and mandible, are considered to be a functional barrier tissue with barrier immunity (13). Uniquely, the oral barrier tissue interfaces the external surface of alveolar bone. Unlike other barrier tissues, the activated immune system in the oral barrier may have a profound effect on the underlying alveolar bone (14–16). These oral risk factors are known to induce oral barrier inflammation and osteoclastogenesis. Therefore, we have hypothesized that osteoclasts associated with the oral barrier tissue may modulate and potentially define the oral barrier immune reaction under the influence of BPs.

Osteoclasts (OCs) are tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells derived from hematopoietic precursors in the myeloid/monocyte lineage that circulate in the blood after their formation in the bone marrow (17–19). M-CSF and RANKL are the essential factors expressed by osteoblasts, stromal cells and lymphocytes required for OCs formation (20). Due to the strong affinity for bone minerals, BPs can preferentially target OCs in a variety of ways, including effects on OCs differentiation and their recruitment to the bone surface (21), inhibition of OCs adhesion (22), inhibition of OCs activity on the bone surface (23, 24), and shortening of OCs life span by promoting apoptosis (25–30). Denosumab is a monoclonal antibody works by targeting RANKL resulting in RANKL inhibition which further blocks OCs maturation, function and survival ultimately reducing bone resorption (31).

Natural killer (NK) cells are known for their effector functions which include direct natural cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), as well as secretion of inflammatory cytokines and chemokines that indirectly regulate the functions of other immune cells (32, 33). Immune and bone cells derive from progenitors in the bone marrow, share a common microenvironment and are influenced by similar mediators. RANKL expressed by CD4+ and CD8+ T-cells can induce osteoclastogenesis, providing a link between the immune and skeletal systems. NK cells have also been identified to express RANKL which during their interaction with monocytes can trigger the formation of osteoclasts (34). IFN-γ binds to its receptor on osteoclasts, degrades RANKL signaling and thus inhibits the activation of osteoclasts and protects our bones from being resorbed. IFN-γ is produced predominantly by NK and natural killer T (NKT) cells involved in the innate immune response, and by CD4⁺ Th1 and CD8⁺ cytotoxic T lymphocyte (CTL) effector T cells, once antigen-specific immunity develops (35). Reduced OCs and NK cell function coexist in osteopetrotic mutant rats (36). OCs are capable of secreting a wide range of cytokines and chemokines (37, 38) and activate CD4+ T cells, CD8+ T cells (37) and NK cells (38, 39).

As recommended to develop BRONJ laboratory animal models allowed investigation on the role of inflammatory and immune cells (40), a number of mouse models have been reported (41). While the mouse model provides the essential model to investigate human pathology, it is widely recognized that human and mouse immune systems may differ (42–44). Humanized-BLT (hu-BLT) mice used in this study represents the most advanced and complete humanized mouse model and is the only known humanized mouse model to displays mucosal immunity (45, 46). Generation of hu-BLT mice was performed by surgically implanting pieces of human fetal liver and thymus tissue under the renal capsule of NSG mice, followed by tail vein IV injection of same-donor CD34⁺ hematopoietic cells to support full reconstitution of the human bone marrow (39, 47, 48).

Due to our long-standing studies on ONJ and studying a number of potential mechanisms for the generation and progression of ONJ in different mouse models (38, 49–51), we aimed at identifying factors that may significantly contribute to the induction and progression of ONJ. In a previous study we established epithelial hyperplasia associated with γδ T cells of mouse or human origin in mouse ONJ-like lesions, and based on these studies we concluded that γδ T cells were unlikely cells to mediate the core mechanisms governing the ONJ; however, they may serve as a critical modifier contributing to the different oral mucosal disease variations in ONJ (49). In another study we determined the core function of myeloid cells in the induction of ONJ. In that study CD11b+GR1^hi cells in bone marrow and Ly6G+ cells in the oral barrier tissue were depleted, and the development of ONJ-like lesion was significantly attenuated when anti-Ly6G (Gr1) antibody was intraperitoneally injected for 5 days during the second week of tooth extraction, suggesting that local modulation of myeloid cells in the oral barrier tissue may provide the basis for pathogenesis and thus therapeutic as well as preventive strategy for ONJ (50). To determine microenvironmental differences between the bone marrow which contributes to built up of the bone and in oral mucosa where ONJ occurs, we demonstrated that intravenous injection of ZOL in mice induced pro-inflammatory microenvironment in bone marrow and demonstrated significant immune activation and function, however, tooth extraction wound of oral gingival tissues exhibited profound immune suppressive microenvironment associated with dysregulated wound healing due to the effect of ZOL which could potentially be responsible for the pathogenesis of ONJ (38, 51). In examining, the most important potential candidates in ONJ generation we observed significant associations between increased IFN-γ secretion and function within the bone marrow where bone regeneration and increased mineralization occurs, and significant suppression of IFN-γ secretion and gene in oral mucosa where ONJ occurs (38, 51). Therefore, we set the task to investigate a number of parameters including peripheral blood immune cell percentages in human, wild-type mice, and humanized-BLT (hu-BLT) mice, and also investigating the function of immune cells, in particular of NK cell in hu-BLT mice after injections of ZOL and denosumab, which are known to cause ONJ. To our knowledge this is the first report on the role of these two agents on the phenotype and function of NK cells and clear demonstration of suppression of IFN-γ secretion in oral barrier mucosa by these two agents in a relevant mouse model of human disease. We also determined the differential effects of ZOL and denosumab on IFN-γ secretion and NK cell-mediated function in various tissue compartments of hu-BLT mice, demonstrating inverse relationship between bone marrow derived immune cells vs. oral mucosa associated immune cells. These results are extremely crucial in our understanding of mechanisms governing ONJ in oral mucosa and the potential means for novel therapeutic discoveries.

Materials and methods

Ethics statement

The UCLA Animal Research Committee reviewed and approved all experimental protocols involving animals (ARC: #1997-136) and procedures were performed in accordance to all federal, state, and local guidelines. Written informed consents approved by UCLA Institutional Review Board (IRB) were obtained from the human blood donors and all the procedures were approved by the UCLA-IRB.

ZOL or denosumab injection and molar tooth extraction in mice

Combined immunodeficient NOD.CB17-Prkdcscid/J and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG lacking T, B, and natural killer cells) were purchased from Jackson Laboratory and Humanized-BLT (hu-BLT; human bone marrow/liver/thymus) mice were prepared on NSG background as previously described (47, 52, 53). Seven weeks old female B6 WT and female Rag2^-/- mice (B6(Cg)-Rag2tm1.1Cgn/J null mutation in recombination-activating gene-2 resulting in the deficiency of B and T lymphocytes) were purchased from the Jackson Laboratory, Bar Harbor, ME. Mice received a bolus intravenous (IV) injection of 500 µg/Kg ZOL or vehicle 0.9% NaCl solution through retro-orbital venous plexus. One week later, maxillary left first molar was extracted, 5.0 mg/kg carprofen was subcutaneously injected, and mice received 5.0 mg/kg carprofen injection every 24 hours for 48 hours (49). Mice were fed gel food (DietGel Recovery, Clear H2O, Westbrook, ME) for 2 weeks and switched to a conventional mouse pellet food. For denosumab group mice received a bolus intravenous (IV) injection of 120 mg/mice or vehicle 0.9% NaCl solution through retro-orbital venous plexus.

Human immune cells isolation and generation of human osteoclasts

Human peripheral blood was obtained from healthy donors after the written informed consent approved by UCLA Institutional Review Board (IRB) was obtained. Human NK and monocytes were purified from PBMCs using specific isolation kit (Stem Cell Technologies, Vancouver, Canada). The purity of NK cells and monocytes populations were found to be greater than 90% and 95%, respectively, based on flow cytometric analysis. Monocytes were differentiated to osteoclasts by treating with M-CSF (25 ng/mL) and RANKL (25 ng/mL) for 21 days.

Mice tissue preparation, and culture of single cell suspension

Hu-BLT, WT and Rag2^-/- mice were euthanized by 100% CO₂ inhalation on week 2 and week 4 after tooth extraction (n=4 in each group and each time point) followed by a cardiac blood perfusion, and tissues (spleen, bone marrow, pancreas and gingiva from the extraction site) were harvested. The gingiva and pancreas were immediately cut into 1mm³ pieces and placed into a digestion buffer containing 1mg/ml collagenase II (gingiva) or collagenase IV (pancreas), 10 U/ml DNAse I, and 1% bovine serum albumin in DMEM and incubated for 20 minutes at 37°C oven with on a 150 rpm shaker. After digestion, the sample was filtered through a 70 µm cell strainer and centrifuged at 1500 rpm for 10 minutes at 4°C. The pellet was re-suspended in DMEM and cells were counted. The spleen was directly mashed and filtered through a 70 µm cell strainer after harvest, and centrifuged for 5 minutes at 1500 rpm at 4°C. The splenic sample was re-suspended in 0.5ml ACK lysis buffer (150mM NH₄Cl, 1mM KHCO₃, 0.1mM EDTA) to eliminate red blood cells and incubated for 5 minutes at room temperature followed by centrifugation for 5 minutes at 1500 rpm at 4°C. The pellet was re-suspended in DMEM and cells counted. Bone marrow cells were isolated by flushing femurs with PBS supplemented with 2% heat-inactivated FBS. RPMI 1640 supplemented with 10% Fetal Bovine Serum (FBS), 1% sodium pyruvate, 1% NEAA and 5% antibiotic/antimycotic was used for the tissue cultures. PBMCs were isolated from peripheral blood using Ficoll-Hypaque centrifugation of heparinized blood specimens. The buffy coats containing PBMCs were harvested, washed, and re-suspended in RPMI 1640 medium. Recombinant IL-2 (1000 U/ml) was used to activate the cells for three days (NIH- BRB).

Surface markers analysis

The dissociated cells were washed and incubated with flow cytometric antibodies (BioLegend, San Diego, CA). IgG2b was used isotype control. After 30 min incubation, the antibody-stained cells were washed and analyzed by flow cytometry (EPICS XL-MCL, Coulter, Miami, FL). The data were evaluated on a computer software package (FlowJo vX, Flowjo, Ashland, OR).

Enzyme-linked immunosorbent assays and multiplex cytokine assay

Human and mouse IFN-γ ELISA kits were purchased from Biolegend (San Diego, CA) and assay was performed as described by manufacturer. The plates were read in a microplate reader at 450 nm to obtain absorbance value. Multiplex assay was conducted as described in the manufacturer’s protocol for each specified kit. Analysis was performed using a Luminex multiplex instrument (MAGPIX, Millipore, Billerica, MA), and data was analyzed using the proprietary software (xPONENT 4.2, Millipore, Billerica, MA).

⁵¹Cr release cytotoxicity assay

The ⁵¹Cr release assay was performed as described previously (54). Briefly, different numbers of effector cells were incubated with ⁵¹Cr–labeled target cells. After a 4-hour incubation period, the supernatants were harvested from each sample and the released radioactivity was counted using the gamma counter. The percentage specific cytotoxicity was calculated as follows:

% C y t o t o x i c i t y = \frac{E x p e r i m e n t a l c p m - s p o n t a n e o u s c p m}{T o t a l c p m - s p o n t a n e o u s c p m}

LU 30/10⁶ is calculated by using the inverse of the number of effector cells needed to lyse 30% of target cells _˟100.

Antibody-dependent cell-mediated cytotoxicity measurements

Osteoclasts (OCs) were ⁵¹Cr–labeled and were incubated for an hour, after which unbound ⁵¹Cr was washed. OCs (1×10⁶ cells/ml) were then left untreated or treated with denosumab (20 μg/ml) or RANKL (25 ng/ml) or a combination of denosumab (20 μg/ml) and RANKL (25 ng/ml) for 30 minutes, and washed with medium to remove excess unbound antibodies. OCs were then cultured with NK cells at various effector to target ratios, and the cytotoxicity against OCs was assessed using the ⁵¹Cr release cytotoxicity assay as described above.

Statistical analysis

The data derived from multiple samples per group were presented as the mean ± SEM. All statistical analyses were performed using the GraphPad Prism-9 software. An unpaired or paired, two-tailed student’s t-test was performed for the statistical analysis for experiments with two groups. One-way ANOVA with a Bonferroni post-test was used to compare different groups for experiments with more than two groups. (n) denotes the number of mice for each experimental condition. Duplicate or triplicate samples were used in the in vitro studies for assessment. The following symbols represent the levels of statistical significance within each analysis: ****(p value<0.0001), ***(p value 0.0001-0.001), **(p value 0.001-0.01), *(p value 0.01-0.05).

Results

Differential proportions of immune cells in peripheral blood of WT mice compared to either hu-BLT mice or humans

Hu-BLT mice was found to exhibit 64-95% human-CD45+ (hu-CD45) immune cells in peripheral blood, bone marrow and spleen ( Figure 1A ). Osteoclasts (OCs) generated from the bone marrow (BM) derived monocytes were multinucleated, tartrate-resistant acid phosphate (TRAP) positive, and expressed hu-CD45 surface marker ( Figure 1B ). When compared immune cell composition within the peripheral blood of hu-BLT mice to human and/or WT mouse, we found that the percentages of CD3+, CD3+CD4+ and CD3+CD8+ T cells in hu-BLT PBMCs were very similar to human PBMCs and not WT mouse PBMCs ( Figure 1C ). Lower NK cells and higher B cells percentages were seen in hu-BLT mice PBMCs compared to human PBMCs ( Figure 1C ). Based on previous work from our lab and other labs, it has been established that human PBMCs exhibit higher numbers of T cells and lower numbers of B cells, whereas WT mouse PBMCs have a higher number of B cells and less T cells, as shown in Figure 1C . Hu-BLT PBMCs have higher numbers of T cells and less B cells, providing evidence that this mouse model is more like the human system and can be an important tool in studying human diseases.

Surface expression of human and mouse CD45 on peripheral blood, bone marrow, splenocytes and bone marrow-derived osteoclasts of hu-BLT mice; comparison of immune cell percentages in human, WT mice and hu-BLT mice PBMCs. Hu-BLT mice acquired humanized hemato-lymphatic system by co-transplantation of human fetal liver and thymus fragments under the renal capsule of NOG/Scid γc-/- immune deficient NSG mice followed by the intravenous injection of autologous CD34+ hematopoietic cells. Eight weeks after tissue implantation, mice were euthanized and tissues were harvested to obtain single cell suspension. PBMCs, bone marrow (BM), and spleen of hu-BLT mice were analyzed for human and mice CD45+ immune cells using flow cytometric analysis **(A)**. Hu-BLT mice BM isolated monocytes were used to generate osteoclasts (OCs) for 21 days as described in Materials and Methods section. On day 21, hu-BLT OCs were washed with 1 X PBS before the pictures were taken by Leica DMI 6000B inverted microscope. Hu-BLT OCs were then treated with Fast Garnet GBC and sodium nitrate (1:1), incubated at 37 degree C for one hour, cells were rinsed and treated with hematoxylin for two mins before pictures were taken by Leica DMI 6000B inverted microscope. Pre- and Post-TRAP-stained pictures are shown in the figure. Hu-BLT OCs were analyzed for human and mice CD45+ immune cells using flow cytometric analysis **(B)**. Immune cell composition was determined in human PBMCs, hu-BLT PBMCs and B6 female WT mice PBMCs using flow cytometric analysis **(C)**.

ZOL-mediated effect on IFN-γ secretion and NK cell-mediated cytotoxicity in hu-BLT mice

To determine the effects of ZOL on the secretion of IFN-γ and NK cell-mediated cytotoxicity, the single cell suspension of peripheral blood, bone marrow, and spleen were cultured in the absence or presence of IL-2 for three days before these functions were determined. ZOL increased IFN-γ secretion and NK cell-mediated cytotoxicity in PBMCs, BM and spleen except NK cell-mediated cytotoxicity per one percent of NK cells was observed lower in ZOL-injected hu-BLT mice BM ( Figure 2 , Table 1 , and Figure S1 ). We also evaluated the percentages of key immune cell subsets in the peripheral blood, BM and spleen of hu-BLT mice after ZOL injection. ZOL increased CD16+CD56+, and CD3+CD4+ T, and decreased CD3+ T, and CD3+CD8+ T in PBMCs ( Table 2 and Figure S2A ); increased CD16+CD56+, CD3+ T, and CD3+CD8+ T, and decreased CD3+CD4+ T cells in BM ( Table 2 and Figure S2B ); increased CD16+CD56+, CD3+ T, and CD3+CD4+ T, and decreased CD3+CD8+ T in spleen ( Table 2 and Figure S2C ).

IFN-γ secretion and NK-cell mediated cytotoxicity of PBMCs, BM, and splenocytes of NACL and ZOL-injected hu-BLT mice. Hu-BLT mice were administered with either 0.9% NACL or ZOL (500 µg/kg) *via* IV as described in Materials and Methods section. Four weeks after injections, mice were euthanized and tissues were harvested to obtain single cell suspension. PBMCs **(A)**, BM cells **(B)**, and splenocytes **(C)** of hu-BLT mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the supernatants were harvested and the levels of IFN-γ were determined using specific ELISA. PBMCs **(A)**, BM cells **(B)**, and splenocytes **(C)** were used as effector cells in standard 4-hour ⁵¹Cr release assay against human OSCSCs tumors. Lytic units (LU) 30/10⁶ cells were determined using inverse number of effector cells required to lyse 30% of OSCSCs × 100. LUs per 1% NK cells were determined using CD16+CD56+ percentages obtained by flow cytometric analysis (n=2) **(A–C)**. **(p value 0.001-0.01), *(p value 0.01-0.05).

Table 1.

= IFN-γ secreted by splenocytes and PBMCs was compared to IFN-γ secreted by BM of NACL and ZOL-injected hu-BLT mice.

A: (NACL+ no tooth extraction)
Bone marrow (n=2)	Spleen (n=2)	Peripheral blood mononuclear cells (n=2)	p values
28.4 (+/- 2.2)	146 (+/- 6)		**
28.4 (+/- 2.2)		858 (+/- 17)	****

Open in a new tab

B: (ZOL + no tooth extraction)
Bone marrow (n=2)	Spleen (n=2)	Peripheral blood mononuclear cells (n=2)	p values
74 (+/-3)	365 (+/- 28)		***
74 (+/-3)		1251 (+/- 5)	****

Open in a new tab

Hu-BLT mice were administered with either 0.9% NACL (A) or ZOL (500 µg/kg) (B) via IV as described in Materials and Methods section. Four weeks after injections, mice were euthanized and tissues were harvested to obtain single cell suspension. BM (n=2), splenocytes (n=2), and PBMCs (n=2) of hu-BLT mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the supernatants were harvested and the levels of IFN-γ were determined using specific ELISA. Statistical analysis was performed to compare the levels of IFN-γ secreted by BM vs. splenocytes or BM vs. PBMCs. ****(p value <0.0001), ***(p value <0.001), **(p value 0.001-0.01).

Table 2.

Immune cell composition of peripheral blood, bone marrow and spleen of NACL and ZOL-injected hu-BLT mice.

	Peripheral blood mononuclear cells		Bone marrow		Spleen
Hu-BLT week 4 (n=2)	NACL	ZOL	NACL	ZOL	NACL	ZOL
% CD16+CD56+	7.4	9.1	2.9	8.7	1.9	3.7
% CD3+	72	58	17	48	28	53
% CD3+CD4+	67	88	73	62	77	84
% CD3+CD8+	34	9	25	38	24	15

Open in a new tab

Hu-BLT mice were administered with either 0.9% NACL or ZOL (500 µg/kg) via IV as described in Materials and Methods section. Four weeks after injections, mice were euthanized and tissues were harvested to obtain single cell suspension. Immune cell composition was determined in PBMCs (n=2), bone marrow (n=2), and splenocytes (n=2) of hu-BLT mice using flow cytometric analysis.

Injection of ZOL decreased IFN-γ secretion but increased NK cell-mediated cytotoxicity in tooth extracted oral gingival tissue of hu-BLT mice

We analyzed the surface receptor expressions for human CD3+ T cells, NK cells (CD16+CD56+) and γδT cells in the gingival tissues recovered from the extraction wound site. Both in week 2 and 4, higher human CD3+ T cells, and less NK and γδT cells were seen in gingival tissue of ZOL-injected as compared to NACL-injected hu-BLT ( Figures 3A, B , Figure S3 ). Both in week 2 and 4, IFN-γ secretion was found significantly lower in ZOL-injected compared to NACL-injected gingival tissue ( Figures 3A, B , S1D , Tables 3 , 4 and Table S3 ). NK cell-mediated cytotoxicity against human oral cancer stem cells was significantly higher in ZOL-injected gingival tissue ( Figures 3A, B ).

Human CD45+ immune cell percentages, IFN-γ secretion and NK-cell mediated cytotoxicity in oral gingival cells of NACL or ZOL-injected and tooth extracted hu-BLT mice. Hu-BLT mice were administered with either 0.9% NACL or ZOL (500 µg/kg) *via* IV followed by maxillary left first molar extraction as described in Materials and Methods section. Two weeks (n=3) **(A)** and four weeks (n=2) **(B)** after injections, mice were euthanized and oral gingival tissues were harvested to obtain single cell suspension. Surface expression of CD45+CD3+, CD45+CD16+CD56+, and CD45+CD3+gdT+ in oral gingival cells were determined using flow cytometric analysis as described in the Materials and Methods. Oral gingival cells mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the supernatants were harvested and the levels of IFN-γ was determined using specific ELISA. IFN-γ secretion was determined per human CD45+ cells using human CD45+ percentages obtained by flow cytometric analysis. IFN-γ per one NK cell were determined using CD16+CD56+ percentages obtained by flow cytometric analysis. Oral gingival cells were used as effector cells in standard 4-hour ⁵¹Cr release assay against human OSCSCs tumors. Lytic units (LU) 30/10⁶ cells were determined using inverse number of effector cells required to lyse 30% of OSCSCs × 100. LU per 1% NK cells were determined using CD16+CD56+ percentages obtained by flow cytometric analysis **(A, B)**. **(p value 0.001-0.01), *(p value 0.01-0.05) ns (no significance).

Table 3.

IFN-γ secreted per one million hu-CD45+ immune cells or per one NK cell in tissue compartments of NACL or ZOL-injected and tooth-extracted hu-BLT mice.

A
IFN-γ/CD45+ cells X 10⁶ Week 2	BLT (NACL+ tooth extraction)	BLT (ZOL + tooth extraction)	Fold change ZOL/NACL	p values row vs. row 3
Bone marrow (n=4)	31 +/- 6	65 +/-9	2.1	**
Spleen (n=4)	131 +/- 9.5	429 +/- 20	3.3	***
Gingiva (n=2)	3 +/- 0.4	0.8 +/- 0.008	0.3	****
Peripheral blood mononuclear cells (n=4)	715 +/- 64	1608 +/- 170	2.25	****
Pancreas (n=3)	7.04 +/- 1	6 +/- 0.8	0.85	ns

Open in a new tab

B
IFN-γ/CD45+ cells X 10⁶ Week 4	BLT (NACL+ tooth extraction)	BLT (ZOL + tooth extraction)	Fold change ZOL/NACL	p values row 2 vs. row 3
Bone marrow (n=4)	45 +/- 7	90 +/- 22	2	**
Spleen (n=4)	180 +/- 12	428 +/- 79	2.4	****
Gingiva (n=2)	4.4 +/- 0.6	0.5 +/- 0.005	0.11	****
Peripheral blood mononuclear cells (n=4)	892 +/- 26	1355 +/- 191	1.5	****
Pancreas (n=3)	8.21 +/- 0.7	8.3 +/- 1.5	1	ns

Open in a new tab

C
IFN-γ/NK Cell Week 2	BLT (NACL+ tooth extraction)	BLT (ZOL + tooth extraction)	Fold change ZOL/NACL	p values row 2 vs. row 3
Bone marrow (n=4)	0.6 +/- 0.15	1.04 +/- 0.23	1.7	*
Spleen (n=4)	5.5 +/- 0.8	13.4 +/- 3	2.4	*
Gingiva (n= 2)	0.31 +/- 0.8	0.06 +/- 0.003	0.2	***
Peripheral blood mononuclear cells (n=4)	89 +/- 11	131 +/- 13	1.5	***
Pancreas (n=3)	0.2 +/- 0.008	0.13 +/- 0.02	0.65	ns

Open in a new tab

D
IFN-γ/NK Cell Week 4	BLT (NACL+ tooth extraction)	BLT (ZOL + tooth extraction)	Fold change ZOL/NACL	p values row 2 vs. row 3
Bone marrow (n=4)	1.1 +/- 0.33	1.9 +/- 1.1	1.7	ns
Spleen (n=4)	7.5 +/- 0.7	11 +/- 3	1.5	*
Gingiva (n=2)	0.5 +/- 0.14	0.04 +/- 0.006	0.08	***
Peripheral blood mononuclear cells(n=4)	113 +/- 6	104 +/- 6	0.9	ns
Pancreas (n=3)	0.2 +/- 0.023	0.4 +/- 0.1	2	*

Open in a new tab

Hu-BLT mice were administered with either 0.9% NACL or ZOL (500 µg/kg) via IV followed by maxillary left first molar extraction as described in Materials and Methods section. Two (A, C) or four (B, D) weeks after tooth extraction, mice were euthanized and tissues were harvested to obtain single cell suspension. BM (n=4), splenocytes (n=4), PBMCs (n=4), oral gingiva (n=2), and pancreas (n=3) of hu-BLT mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the supernatants were harvested and the levels of IFN-γ were determined using specific ELISA. Levels of IFN-γ secreted was determined based on one million human CD45+ immune cells (A, B) or based on one NK cell (C, D). ****(p value <0.0001), ***(p value <0.001), **(p value 0.001-0.01), *(p value 0.01-0.05) ns, no-significance.

Table 4.

IFN-γ secreted by splenocytes, PBMCs, gingiva, and pancreas was compared to IFN-γ secreted by BM of NACL and ZOL-injected and tooth-extracted hu-BLT mice.

A: (NACL+ tooth extraction) week 2
Bone marrow (n=4)	Spleen (n=4)	Peripheral blood mononuclear cells (n=4)	Gingiva (n=2)	Pancreas (n=3)	p values
31 +/-6	131 +/- 9.5				****
31 +/-6		715 +/- 64			****
31 +/-6			3 +/- 0.4		**
31 +/-6				7.04 +/- 1	***

Open in a new tab

B: (ZOL + tooth extraction) week 2
Bone marrow (n=4)	Spleen (n=4)	Peripheral blood mononuclear cells (n=4)	Gingiva (n=2)	Pancreas (n=3)	p values
65 +/- 9	429+/- 20				****
65 +/- 9		1608 +/-170			****
65 +/- 9			0.8 +/-0.008		****
65 +/- 9				6 +/- 0.8	***

Open in a new tab

C: (NACL+ tooth extraction) week 4
Bone marrow (n=4)	Spleen (n=4)	Peripheral blood mononuclear cells (n=4)	Gingiva (n=2)	Pancreas (n=3)	p values
45 +/- 7	180 +/- 12				****
45 +/- 7		892 +/- 26			****
45 +/- 7			4.4 +/- 0.6		*
45 +/- 7				8.21 +/- 0.7	**

Open in a new tab

D: (ZOL + tooth extraction) week 4
BM (n=4)	Spleen (n=4)	Peripheral blood mononuclear cells (n=4)	Gingiva (n=2)	Pancreas (n=3)	p values
90 +/- 22	428 +/- 79				***
90 +/- 22		1355 +/- 191			****
90 +/- 22			0.5 +/- 0.005		**
90 +/- 22				8.3 +/- 1.5	**

Open in a new tab

Hu-BLT mice were administered with either 0.9% NACL (A, C) or ZOL (500 µg/kg) (B, D) via IV followed by maxillary left first molar extraction as described in Materials and Methods section. Two (A, B) or four (C, D) weeks after tooth extraction, mice were euthanized and tissues were harvested to obtain single cell suspension. BM (n=4), splenocytes (n=4), PBMCs (n=4), oral gingiva (n=2), and pancreas (n=3) of hu-BLT mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the supernatants were harvested and the levels of IFN-γ were determined using specific ELISA. Levels of IFN-γ secreted was determined based on human CD45+ immune cells, and statistical analysis was performed to compare the levels of IFN-γ secreted by BM vs. splenocytes or BM vs. PBMCs. ****(p value <0.0001), ***(p value <0.001), **(p value 0.001-0.01), *(p value 0.01-0.05).

Effect of ZOL injection on IFN-γ secretion and key immune cells in PBMCs, BM, spleen and pancreas of tooth-extracted hu-BLT mice

We determined the effect of ZOL in combination with tooth extraction on IFN-γ secretion, and found higher IFN-γ secretion in PBMCs, bone marrow and spleen of the ZOL-injected hu-BLT mice in week 2 and 4 after tooth extraction ( Figures 4A, B , Tables 3 , 4 , and Figures S4, S5 ). In pancreas, IFN-γ secretion was found higher both of week 2 and 4 ( Figure S4 ), IFN-γ secretion per hu-CD45+ immune cells and per one NK cell were found lower on week 2 ( Figure 4A and Table 3 ), but on week 4 similar levels were seen for IFN-γ secretion per hu-CD45+ immune cells and higher per one NK cell in ZOL-injected hu-BLT mice ( Figure 4B and Table 3 ). In both week 2 and 4, NACL and ZOL injected mice, IFN-γ secretion level order was PBMCs > spleen > BM > pancreas > gingiva ( Table 4 ). The secretion levels of TNF-α and IL-6 were found to be higher in PBMCs, bone marrow and spleen of the ZOL-injected hu-BLT mice in week 2 and 4 ( Figure S5 ). Next, we evaluated the percentages of key immune cell subsets in the peripheral blood, BM, spleen, and pancreas of ZOL and NACL injected tooth-extracted hu-BLT mice. On week 2, ZOL-injected tooth-extracted hu-BLT PBMCs and spleen showed increased CD16+CD56+, and CD3+ T; BM showed increased CD16+CD56+, and decreased CD3+ T cells; pancreas showed similar CD16+CD56+, and increased CD3+ T ( Table S4 , and Figure S6 ). On week 4, ZOL-injected tooth-extracted hu-BLT PBMCs showed increased CD16+CD56+, CD3+CD4+ T, and decreased CD3+ T, and CD3+CD8+ T cells; BM showed increased CD16+CD56+, CD3+ T, and CD3+CD8+ T, and decreased CD3+CD4+ T; spleen increased CD16+CD56+, CD3+ T, and CD3+CD4+ T, and decreased CD3+CD8+ T cells; pancreas increased CD16+CD56+, CD3+ T, CD3+CD4+ T, and decreased CD3+CD8+ T cells ( Table 5 , and Figure S6 ).

IFN-γ secretion in PBMCs, BM, spleen and pancreas of NACL or ZOL-injected and tooth-extracted hu-BLT mice. Hu-BLT mice were administered with either 0.9% NACL or ZOL (500 µg/kg) *via* IV followed by maxillary left first molar extraction as described in Materials and Methods section. Two **(A)** or four weeks **(B)** after tooth extraction, mice were euthanized and tissues were harvested to obtain single cell suspension. PBMCs (n=4), BM (n=4), splenocytes (n=4), and pancreas (n=3) of hu-BLT mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the supernatants were harvested and the levels of IFN-γ were determined using specific ELISA. IFN-γ secretion per human CD45+ cell was determined using CD45 percentages obtained by flow cytometric analysis. IFN-γ per one NK cell was determined using CD16+CD56+ percentages obtained by flow cytometric analysis **(A, B)**. ****(p value<0.0001), ***(p value<0.001), **(p value 0.001-0.01), *(p value 0.01-0.05), ns (no significance).

Table 5.

Percentages of immune cells in PBMCs, BM, splenocytes and pancreas of NACL or ZOL-injected and tooth-extracted hu-BLT mice.

Hu-BLT week 4 (n=4)	Peripheral blood mononuclear cells		Bone marrow		Spleen		Pancreas
	NACL	ZOL	NACL	ZOL	NACL	ZOL	NACL	ZOL
% CD16+CD56+	6	8.3	2.7	5.1	2.3	4.04	2.3	5.2
% CD3+	68	55.3	16.5	30.5	28	51.3	40.5	60.3
% CD3+CD4+	63	78.5	66	54	74	85	20	25
% CD3+CD8+	37	21.5	35	46	26.3	15	80	75

Open in a new tab

Hu-BLT mice were administered with either 0.9% NACL or ZOL (500 µg/kg) via IV followed by maxillary left first molar extraction as described in Materials and Methods section. Four weeks after tooth extraction, mice were euthanized and tissues were harvested to obtain single cell suspension. Immune cell composition was determined in PBMCs (n=4), BM (n=4), splenocytes (n=4), and pancreas (n=3) of hu-BLT mice using flow cytometric analysis.

Effect of ZOL injection on NK cell-mediated cytotoxicity in PBMCs, BM, spleen and pancreas of tooth-extracted hu-BLT mice

On week 2, NK cell-mediated cytotoxicity against human oral cancer stem cells was higher in PBMCs, bone marrow and spleen, and lower in pancreas of ZOL-injected hu-BLT mice ( Figure 5A ). On week 4, NK cell-mediated cytotoxicity against human oral cancer stem cells was slightly lower in PBMCs, but continued to be higher in bone marrow and spleen, and significantly lower in pancreas in ZOL-injected hu-BLT ( Figure 5B ).

NK cell-mediated cytotoxicity in PBMCs, BM, spleen and pancreas of NACL or ZOL-injected and tooth-extracted hu-BLT mice. Hu-BLT mice were administered with either 0.9% NACL or ZOL (500 µg/kg) *via* IV followed by maxillary left first molar extraction as described in Materials and Methods section. Two **(A)** or four weeks **(B)** after tooth extraction, mice were euthanized and tissues were harvested to obtain single cell suspension. PBMCs (n=4), BM (n=4), splenocytes (n=4), and pancreas (n=3) of hu-BLT mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the cells were used as effector cells in standard 4-hour ⁵¹Cr release assay against human OSCSCs tumors. Lytic units (LU) 30/10⁶ cells were determined using inverse number of effector cells required to lyse 30% of OSCSCs × 100. LUs per 1% NK cell were determined using CD16+CD56+ percentages obtained by flow cytometric analysis **(A, B)***. ***(p value<0.001), **(p value 0.001-0.01), *(p value 0.01-0.05)*, ns (no significance).

Denosumab-mediated effect in IFN-γ secretion and NK cell-mediated cytotoxicity in hu-BLT mice

To determine the effects of denosumab on the secretion of IFN-γ and NK cell-mediated cytotoxicity, the single cell suspension of peripheral blood, bone marrow, spleen, pancreas and gingiva were treated with IL-2 for three days before these functions were determined. Higher levels of IFN-γ secretion were observed in BM, but decreased in PBMCs, spleen, pancreas, and gingiva of denosumab-injected hu-BLT mice ( Figure 6A ). NK cell-mediated cytotoxicity was also increased in BM but decreased in PBMCs and spleen of denosumab-injected hu-BLT mice ( Figures 6B, C ). Denosumab increased CD3+CD8+, and decreased CD3+, and CD3+CD4+ T in PBMCs ( Figure S7A ); increased CD16+CD56+, CD3+ CD8+ T and decreased CD3+CD4+ T in BM ( Figure S7B ); increased CD3+CD8+ T, and CD16+CD56+, CD3+, and CD3+CD4+ T cells in spleen ( Figure S7C ).

IFN-γ secretion and NK-cell mediated cytotoxicity in NACL and denosumab-injected hu-BLT mice. Hu-BLT mice were administered with either 0.9% NACL or denosumab (120 mg/mice) *via* IV as described in Materials and Methods section. Four weeks after injections, mice were euthanized and tissues were harvested to obtain single cell suspension. PBMCs (n=2), BM cells (n=2), splenocytes (n=2), pancreas (n=2), and gingiva (n=3) of hu-BLT mice were cultured (2 × 10⁶ cells/2ml) with IL-2 (1000 U/ml) for three days, after which the supernatants were harvested and the levels of IFN-γ were determined using specific ELISA **(A)**. PBMCs (n=2), BM cells (n=2), and splenocytes (n=2) were used as effector cells in standard 4-hour ⁵¹Cr release assay against human OSCSCs tumors. Lytic units (LU) 30/10⁶ cells were determined using inverse number of effector cells required to lyse 30% of OSCSCs × 100 **(B)**. LUs per 1% NK cells were determined using CD16+CD56+ percentages obtained by flow cytometric analysis (n=2) **(C)**. ***(p value 0.0001-0.001), **(p value 0.001-0.01), *(p value 0.01-0.05), ns (no significance).

Higher levels of NK cell-mediated ADCC were seen against OCs treated with a combination of denosumab and RANKL

We treated human OCs with denosumab alone or with a combination of denosumab and RANKL followed by surface analysis using flow cytometer ( Figure 7A ). Later, we determined the antibody dependent cell-mediated cytotoxicity (ADCC) using untreated or denosumab or RANKL or a combination of denosumab and RANKL treated human OCs as targets and IL-2 treated human NK cells as effectors. Although no ADCC was seen when OCs were with denosumab or RANKL alone, but significant levels of ADCC was seen when OCs were treated with a combination of denosumab and RANKL ( Figure 7B ).

Higher levels of NK cell-mediated ADCC was seen against OCs treated with a combination of denosumab and RANKL. Human OCs were generated as described in the Materials and Methods. OCs were left untreated or treated with denosumab (20 μg/ml) or RANKL (25 ng/ml) or a combination of denosumab (20 μg/ml) and RANKL (25 ng/ml) for 30 minutes. The unbounded antibodies were washed away, and the surface expression levels were analyzed after cells were stained with goat anti-human FITC using flow cytometry. IgG2 isotype antibodies were used as controls. One of three representative experiments is shown in the figure **(A)**. OCs were generated as described in the Materials and Methods. Purified NK cells (1×10⁶ cells/ml) from healthy individuals were treated with IL-2 (1000 U/ml) for 18 hours and were as effectors in chromium release assay. OCs were labeled with ⁵¹Cr for an hour after which cells were washed to remove unbound ⁵¹Cr. ⁵¹Cr-labeled OCs were then left untreated or treated with denosumab (20 μg/ml) or RANKL (25 ng/ml) or a combination of denosumab (20 μg/ml) and RANKL (25 ng/ml) for 30 minutes. The unbounded antibodies were washed away, and the cytotoxicity against the OCs was determined using a standard 4-6 hour ⁵¹Cr release assay. The lytic units (LU) 30/10⁶ cells were determined using the inverse number of NK cells required to lyse 30% of OCs × 100 (n=3) **(B)**. *(p value 0.01-0.05).

Discussion

Many attempts were made to delineate the underlying mechanisms of osteonecrosis of the jaw (ONJ) in patients receiving either bisphosphonates or denosumab previously. Our findings indicate that gingiva unlike peripheral blood, bone marrow, or spleen have different dynamics of immune function and regulation. Although we have observed increased immune function by bisphosphonate ZOL and denosumab in BM, both in terms of NK cell-mediated cytotoxicity and secretion of IFN-γ, other tissue compartments such as PBMCs, spleen and gingiva have distinct profiles. Both PBMCs and spleen were able to exhibit higher NK cell-mediated cytotoxicity and secretion of IFN-γ when activated by ZOL in comparison to NACL, but the injection of denosumab exhibited lower NK cell-mediated cytotoxicity and secretion of IFN-γ in PBMCs and spleen when compared to NACL in hu-BLT mice, suggesting different mechanisms of action in the peripheral tissues between ZOL and denosumab, ultimately leading to the induction of ONJ. However, in both cases the gingival immune cells had much lower ability to increase IFN-γ secretion. Indeed, ZOL injection delayed wound healing after tooth extraction in tooth socket of hu-BLT mice after 4 weeks of treatment suggestive of ONJ (manuscript in prep), whereas NACL injection did not exhibit such aberrations in the tooth socket after tooth extraction. Upon histological examination, on week 4 after tooth extraction and injection of ZOL many inflammatory cells were remaining in the connective tissue immediately adjacent to the bone with larger and prominent areas of necrotic bone, whereas in NACL injected mice the wound had already resolved, with very few inflammatory cells remaining in the connective tissue and a lack of necrotic bone lesions (manuscript in prep). Such abnormal manifestations by ZOL within the tooth socket could be due to the abnormal induction of immune activation, in particular suppression of IFN-γ secretion and elevated NK cell-mediated cytotoxicity adjacent to bone as detailed in our studies.

There are a number of differences between the WT mice and hu-BLT mice in terms of their response to ZOL activation before and after tooth extraction. WT mice has in general higher percentages of B cells and lower percentages of T cells whereas the proportions of immune cell subsets are similar between the human PBMCs and reconstituted hu-BLT PBMCs with some slight differences in the proportions of NK cells in hu-BLT mice in comparison to humans (55) ( Figure 1C ). In three different mice models of WT, Rag2^-/- and hu-BLT, four weeks after tooth extraction, the fold increase of IFN-γ secretion in BM cells by ZOL vs. NACL treatment was 4.85 for WT, 1.4 for Rag2^-/- and 2.7 for hu-BLT mice. Therefore, BM cells of WT mice had higher ability to upregulate IFN-γ secretion with ZOL whereas Rag2^-/- mice had the lowest ability and hu-BLT mice was intermediate. When examining the ratio of spleen to BM, WT mice without any injection or tooth extraction had 1.83 fold increase whereas with tooth extraction and NACL injection it was 1.7 fold and with ZOL injection it was 0.92 ( Table S1 ). In Rag2^-/- mice the fold increase of spleen to BM was 1.19, 1, and 0.375 for no tooth extraction in the absence of injection, and tooth extraction with NACL injection, and tooth extraction with ZOL injection, respectively ( Table S2 ). These results indicated that the higher fold of activation and release of IFN-γ in BM cells resulted in lower upregulation of splenocytes in terms of IFN-γ secretion. In contrast the differences between spleen and BM for hu-BLT mice was 8.06 for no tooth extraction and no injection, and the levels decreased to 4.98 and 5.45 fold in week 2 of tooth extraction with NACL and ZOL injection, respectively. The fold differences of IFN-γ between spleen and BM for hu-BLT mice four weeks after tooth extraction was 4.97 with NACL and 3.98 with ZOL ( Table S3 ). These results suggested that if BM cells receive no or lower signals to increase IFN-γ, the periphery will have capability to increase IFN-γ at an increased level. Indeed, PBMCs from the hu-BLT without tooth extraction or injection has ability to upregulate 53 fold when compared to BM cells and that fold decreased to 15.9 and 11.82 for week 2 extractions with NACL and ZOL injections, respectively, and 13.2 and 9.33 for week 4 tooth extractions with NACL and ZOL, respectively, again emphasizing the observation that if BM immune cells receive no or lower signals to increase IFN-γ, immune cells within the peripheral blood and tissues will be able to increase IFN-γ at a much higher levels. Therefore, the higher the increase in BM cells, the lower will be the activation in the periphery. These observations may go beyond the effect of ZOL and denosumab, and implicate other activating agents/signals in which they are involved in the stimulation or priming of the BM, thus affecting the magnitude of increase in immune function in the periphery, or even play a major role in the ultimate effectiveness of peripheral immune cells in elimination or control of infections and malignancies. Therefore, signaling and activation of immune effectors in BM is likely to affect the levels and activation of the immune function in the peripheral blood and tissues.

We have also observed higher percentages of NK cells almost in all tissues of hu-BLT mice after ZOL injections regardless of either it was with tooth extraction or no tooth extraction. NK cell-mediated cytotoxicity and secretion of IFN-γ was higher for BM, spleen and PBMCs after ZOL injection when compared to NACL, whereas pancreas showed decreased NK cell-mediated cytotoxicity and similar or increased secretion of IFN-γ with ZOL. In gingiva, we observed significantly less IFN-γ after ZOL injection but higher NK cell-mediated cytotoxicity. In our previous paper, we have shown that ZOL injection in WT and Rag2^-/- mice resulted in a severe decrease in IFN-γ secretion in the gingiva and the higher increase in BM resulting in higher suppression in the gingiva (51). Therefore, although we see variable results in secretion of IFN-γ in BM, spleen and PBMCs, we always see suppression in the gingiva in WT, Rag2^-/- , or hu-BLT mice. Similar results were also observed when denosumab was injected in hu-BLT mice. In no tooth extraction model injection of denosumab increased the levels of IFN-γ secretion in BM but decreased in other tissues we tested, with gingiva having the most severe decreases. The fold increase of IFN-γ secretion when spleen was compared with BM in the absence of denosumab injection was 8.5 fold, but in the presence of denosumab injection it was 3.12. Based on these results, it appears that denosumab is more suppressive for the peripheral tissues when compared to ZOL. Indeed, in all the peripheral tissues, including PBMCs, splenocytes, pancreas and gingiva the fold increase to BM were all lower. Thus, the dynamics of NK cells’ activation by ZOL and denosumab in BM and peripheral tissues are distinct in hu-BLT mice, although both lead to suppression of IFN-γ secretion in gingiva. It is likely that different mechanisms are used for NK cells suppression by these two drugs. In both cases if stromal cells are unable to undergo differentiation and retain their stem like phenotype, it is likely that they will be targeted by the NK cells leading to ONJ, since stem cells are major targets of NK cells (56).

Increased NK cell-mediated cytotoxicity in the presence of decreased IFN-γ secretion in gingiva after ZOL and denosumab injection may suggest that NK cells may be cytotoxic to stromal cells which have not received signals to undergo differentiation due to the lack of IFN-γ secretion from the NK cells since IFN-γ is an important cytokine to drive differentiation of the cells (57, 58). At present it is not clear why the gingival NK cells show decreased IFN-γ secretion, however, as indicated above, if BM-derived NK cells receive higher signals and are primed and activated within the BM, which we have shown in three different mouse models, depending on the quality and quantity of signals that they receive in the periphery, this may determine their ultimate fate in the gingiva. However, it is not clear why gingival NK cells retain their cytotoxic function but lose ability to secrete IFN-γ. This is the opposite of split anergy in NK cells, which we have coined previously to indicate the function of NK cells which have lost ability to kill stem cells but retained the ability to secrete cytokines (59). It is conceivable to think that NK cells may contain preformed granules that upon contact can deliver to the targets even in situations where they are unable to proliferate or secrete cytokines. These scenarios should await future investigations.

Although the percentages of the NK cells are lower in the gingiva after ZOL treatment (on average 12.2% for NACL injected mice and 6.8% for ZOL injected mice for week 2 after extraction, and 11% and 5.5% for NACL and ZOL injected mice respectively on Week 4 after tooth extraction), they still exhibited increased cytotoxicity but lower secretion of IFN-γ, suggesting that these cells are locally primed and activated, however, their activation may be limited since there is a suppression of IFN-γ secretion. Since T cell activation can also contribute to IFN-γ secretion, the sum of suppression in T and NK cells and potentially other immune subtypes may contribute to the overall suppression of IFN-γ in the gingival tissues. Suppression of IFN-γ secretion in gingival cells could be due to activation induced cell death leading to immunosuppression, since the local microenvironment in the oral cavity is laden with bacteria, food particles etc. that may over activate, already highly primed immune cells by the ZOL or denosumab. Therefore, over activation of gingival immune cells with the sum of all activating signals may be the cause of exhaustion, senescence and activation induced cell death resulting in immune suppression. Indeed, in WT, Rag2^-/- and hu-BLT mice gingiva exhibited significant suppression of IFN-γ secretion, whereas it was variable in PBMCs, spleen and pancreas depending on the mouse model. In addition, all the three mouse models tested in this study also have in common activation of bone marrow cells with ZOL and denosumab. Therefore, studies from WT mice should be interpreted cautiously, when extrapolating to human disease since the dynamics of immune activation in the peripheral tissues are very different between the WT and hu-BLT mice. Rag2^-/- mice has the most severe suppression of the IFN-γ in the gingival tissues, and the highest activation of cells within the BM and other peripheral tissues (51).

To understand the mechanisms by which denosumab can increase bone formation resulting in the reversal or decrease in progression of osteoporosis, we undertook studies to determine the potential mechanisms by which this antibody may act on osteoclasts. Differentiated OCs present receptors for RANK on the surface and are susceptible to antibody dependent cellular cytotoxicity when denosumab is added in the presence of RANKL. It appears that in the absence of RANKL, denosumab does not increase ADCC substantially, indicating that RANKL should be provided by other immune effectors in the microenvironment and that OCs themselves may not produce high levels of RANKL. RANKL is known to be provided by a number of lymphocytes such as T and NK cells (60, 61). Therefore, denosumab mediated effect could be due to the decrease in the bone resorptive function of osteoclasts due to the induction ADCC and killing of OCs, whereas ZOL mediated effects on OCs cell death could be due to a completely different mechanism.

IFN-γ can function both as a pro- or anti-resorptive cytokine, but the reasons for why IFN-γ has variable effects in bone is unknown. IFN-γ was shown to have both direct anti-osteoclastogenic and indirect pro-osteoclastogenic properties in vivo (62). It has been shown that IFN-γ blunts OCs formation through direct targeting of OCs precursors but indirectly stimulates OCs formation and promotes bone resorption by stimulating antigen-dependent T cell activation and T cell secretion of the osteoclastogenic factors RANKL and TNF-α. Thus, the effect of IFN-γ on OCs are variable and may dependent on their maturational stages. However, IFN-γ has many important functions on other cells including osteoblasts and immune cells and, proper induction of this cytokine is imperative for the functioning of the immune cells and osteoblasts in addition to OCs. Suppression of IFN-γ in gingiva may be responsible for the inhibition of immune cells function, subsequently leading to dysregulated osteoblastic and osteoclastic activities. Restoration of IFN-γ in the local microenvironment may result in establishment of homeostatic balance in the gingiva and prevention of ONJ.

OCs are important regulators of osteoblasts and balanced functioning osteoclast/osteoblast is imperative for bone health. We have previously shown that OCs are important and are key activators of the NK cells. Therefore, OCs have significant capacity to modulate the function of the immune cells, changing the fate of osteoblast differentiation and function. The interplay between the CD4+ or CD8+ T cells and γδ T cells and NK cells and OCs within the bone microenvironment is currently being unraveled and future investigations should focus on the interaction of these cells within the bone microenvironment.

Similar to our studies, previous studies in patients with multiple myeloma indicated decrease in the levels of TGF-β, VEGF and a number of other cytokines in BRONJ patients (63). One of the limitations of our studies is the lack of comparative studies between patients who suffer from ONJ and our results from humanized mice. Although our model of study ONJ in hu-BLT does not contain cancer, there are some parallels with human cancer patients in which there are lower percentages of NK cells in hu-BLT mice ( Figure 1C ) similar to patients with cancer (55, 64–67). Such similarities may provide the rationale for the extension of studies from hu-BLT mice to humans with ONJ. However, for the sake of direct comparisons we intend to implant tumors in hu-BLT mice and study the effect of ZOL and Denosumab in the setting of cancer in our future experiments.

Data availability statement

The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by UCLA Institutional Review Board (IRB). The patients/participants provided their written informed consent to participate in this study.

Author contributions

KaK performed all the experiments, analyzed the results, and wrote the manuscript. YS, KeK, KM, and AH assisted KaK in in-vivo work. IN was the co-principal investigator, obtained the funding and designed the study. AJ was the principal investigator, obtained the funding, designed the study, and wrote the manuscript along with first author. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1111627/full#supplementary-material

Click here for additional data file.^{(6.3MB, docx)}

References

1. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci (2007) 1117:209–57. doi: 10.1196/annals.1402.089 [DOI] [PubMed] [Google Scholar]
2. Park S, Kanayama K, Kaur K, Tseng HC, Banankhah S, Quje DT, et al. Osteonecrosis of the jaw developed in mice: Disease variants regulated by gammadelta T cells in oral mucosal barrier immunity. J Biol Chem (2015) 290(28):17349–66. doi: 10.1074/jbc.M115.652305 [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol (2007) 4(1):42–55. doi: 10.1038/ncponc0688 [DOI] [PubMed] [Google Scholar]
4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol (2005) 23(34):8580–7. doi: 10.1200/JCO.2005.02.8670 [DOI] [PubMed] [Google Scholar]
5. Dehari H, Tomihara K, Ueda M, Shimanishi M, Ono M, Sasaki T, et al. [Clinical investigation of bisphosphonate-related osteonecrosis of the jaws]. Gan To Kagaku Ryoho (2009) 36(13):2587–92. [PubMed] [Google Scholar]
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg (2003) 61(9):1115–7. doi: 10.1016/S0278-2391(03)00720-1 [DOI] [PubMed] [Google Scholar]
7. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg (2003) 61(9):1104–7. doi: 10.1016/S0278-2391(03)00328-8 [DOI] [PubMed] [Google Scholar]
8. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg (2004) 62(5):527–34. doi: 10.1016/j.joms.2004.02.004 [DOI] [PubMed] [Google Scholar]
9. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2012) 23(5):1341–7. doi: 10.1093/annonc/mdr435 [DOI] [PubMed] [Google Scholar]
10. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg (2012) 41(11):1397–403. doi: 10.1016/j.ijom.2012.06.020 [DOI] [PubMed] [Google Scholar]
11. Thumbigere-Math V, Michalowicz BS, Hodges JS, Tsai ML, Swenson KK, Rockwell L, et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol (2014) 85(2):226–33. doi: 10.1902/jop.2013.130017 [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol (2009) 27(32):5356–62. doi: 10.1200/JCO.2009.21.9584 [DOI] [PubMed] [Google Scholar]
13. Cortes-Vieyra R, Rosales C, Uribe-Querol E. Neutrophil functions in periodontal homeostasis. J Immunol Res (2016) 2016:1396106. doi: 10.1155/2016/1396106 [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Silva N, Dutzan N, Hernandez M, Dezerega A, Rivera O, Aguillon JC, et al. Characterization of progressive periodontal lesions in chronic periodontitis patients: levels of chemokines, cytokines, matrix metalloproteinase-13, periodontal pathogens and inflammatory cells. J Clin Periodontol (2008) 35(3):206–14. doi: 10.1111/j.1600-051X.2007.01190.x [DOI] [PubMed] [Google Scholar]
15. Cheng WC, Hughes FJ, Taams LS. The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol (2014) 41(6):541–9. doi: 10.1111/jcpe.12238 [DOI] [PubMed] [Google Scholar]
16. Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, Dutzan N, et al. Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med (2014) 6(229):229ra40. doi: 10.1126/scitranslmed.3007696 [DOI] [PMC free article] [PubMed] [Google Scholar]
17. Chambers TJ, Fuller K, McSheehy PM, Pringle JA. The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol (1985) 145(4):297–305. doi: 10.1002/path.1711450403 [DOI] [PubMed] [Google Scholar]
18. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev (1992) 13(1):66–80. doi: 10.1210/edrv-13-1-66 [DOI] [PubMed] [Google Scholar]
19. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 2(4):389–406. doi: 10.1016/S1534-5807(02)00157-0 [DOI] [PubMed] [Google Scholar]
20. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 473(2):139–46. doi: 10.1016/j.abb.2008.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 1(1):27–39. [PubMed] [Google Scholar]
22. Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int (1998) 63(3):230–5. doi: 10.1007/s002239900519 [DOI] [PubMed] [Google Scholar]
23. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int (1991) 49(6):407–15. doi: 10.1007/BF02555852 [DOI] [PubMed] [Google Scholar]
24. Piper K, Boyde A, Jones SJ. The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number. Calcif Tissue Int (1994) 54(1):56–61. doi: 10.1007/BF00316291 [DOI] [PubMed] [Google Scholar]
25. Hiroi-Furuya E, Kameda T, Hiura K, Mano H, Miyazawa K, Nakamaru Y, et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int (1999) 64(3):219–23. doi: 10.1007/s002239900606 [DOI] [PubMed] [Google Scholar]
26. Lerner UH, Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro . Bone (1987) 8(3):179–89. doi: 10.1016/8756-3282(87)90018-4 [DOI] [PubMed] [Google Scholar]
27. Ito M, Amizuka N, Nakajima T, Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone (1999) 25(4):447–52. doi: 10.1016/S8756-3282(99)00197-0 [DOI] [PubMed] [Google Scholar]
28. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, et al. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res (1998) 13(11):1721–9. doi: 10.1359/jbmr.1998.13.11.1721 [DOI] [PubMed] [Google Scholar]
29. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo . J Bone Miner Res (1995) 10(10):1478–87. doi: 10.1002/jbmr.5650101008 [DOI] [PubMed] [Google Scholar]
30. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol (1996) 50(5):1127–38. [PubMed] [Google Scholar]
31. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: Mechanism of action and clinical outcomes. Int J Clin Pract (2012) 66(12):1139–46. doi: 10.1111/ijcp.12022 [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Fildes JE, Yonan N, Leonard CT. Natural killer cells and lung transplantation, roles in rejection, infection, and tolerance. Transpl Immunol (2008) 19(1):1–11. doi: 10.1016/j.trim.2008.01.004 [DOI] [PubMed] [Google Scholar]
33. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev (2006) 20(3):123–37. doi: 10.1016/j.blre.2005.10.001 [DOI] [PubMed] [Google Scholar]
34. Soderstrom K, Stein E, Colmenero P, Purath U, Muller-Ladner U, de Matos CT, et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci United States America (2010) 107(29):13028–33. doi: 10.1073/pnas.1000546107 [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Delves PJ, Roitt IM. The immune system. second of two parts. N Engl J Med (2000) 343(2):108–17. doi: 10.1056/NEJM200007133430207 [DOI] [PubMed] [Google Scholar]
36. Popoff SN, Jackson ME, Koevary SB, Marks SC, Jr. Coexistence of reduced function of natural killer cells and osteoclasts in two distinct osteopetrotic mutations in the rat. J Bone Miner Res (1991) 6(3):263–71. doi: 10.1002/jbmr.5650060308 [DOI] [PubMed] [Google Scholar]
37. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood (2010) 116(2):210–7. doi: 10.1182/blood-2009-11-255026 [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Tseng HC, Kanayama K, Kaur K, Park SH, Park S, Kozlowska A, et al. Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget (2015) 6(24):20002–25. doi: 10.18632/oncotarget.4755 [DOI] [PMC free article] [PubMed] [Google Scholar]
39. Kozlowska AK, Kaur K, Topchyan P, Jewett A. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice. Cancer Immunol Immunother (2016) 65(7):835–45. doi: 10.1007/s00262-016-1822-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res (2007) 22(10):1479–91. doi: 10.1359/jbmr.0707onj [DOI] [PubMed] [Google Scholar]
41. Allen MR, Ruggiero SL. Osteonecrosis of the jaw: Recent clinical and preclinical advances. IBMS BoneKEy (2011) 8(3):141–53. doi: 10.1138/20110500 [DOI] [Google Scholar]
42. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 172(5):2731–8. doi: 10.4049/jimmunol.172.5.2731 [DOI] [PubMed] [Google Scholar]
43. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U.S.A. (2013) 110(9):3507–12. doi: 10.1073/pnas.1222878110 [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Tao L, Reese TA. Making mouse models that reflect human immune responses. Trends Immunol (2017) 38(3):181–93. doi: 10.1016/j.it.2016.12.007 [DOI] [PubMed] [Google Scholar]
45. Stoddart CA, Maidji E, Galkina SA, Kosikova G, Rivera JM, Moreno ME, et al. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. Virology (2011) 417(1):154–60. doi: 10.1016/j.virol.2011.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
46. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 12(11):786–98. doi: 10.1038/nri3311 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2010) 115(8):1534–44. doi: 10.1182/blood-2009-04-215855 [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, et al. Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J Vis Exp (2012) 70):e4181. doi: 10.3791/4181 [DOI] [PMC free article] [PubMed] [Google Scholar]
49. Park S, Kanayama K, Kaur K, Tseng HC, Banankhah S, Quje DT, et al. Osteonecrosis of the jaw developed in mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY. J Biol Chem (2015) 290(28):17349–66. doi: 10.1074/jbc.M115.652305 [DOI] [PMC free article] [PubMed] [Google Scholar]
50. Sun Y, Kaur K, Kanayama K, Morinaga K, Park S, Hokugo A, et al. Plasticity of myeloid cells during oral barrier wound healing and the development of bisphosphonate-related osteonecrosis of the jaw. J Biol Chem (2016) 291(39):20602–16. doi: 10.1074/jbc.M116.735795 [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Kaur K, Kanayama K, Wu QQ, Gumrukcu S, Nishimura I, Jewett A. Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2(-/-) mice; stark differences between the bone marrow and gingivae. Cell Immunol (2022) 375:104526. doi: 10.1016/j.cellimm.2022.104526 [DOI] [PubMed] [Google Scholar]
52. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U.S.A. (2011) 108(51):E1408–16. doi: 10.1073/pnas.1115050108 [DOI] [PMC free article] [PubMed] [Google Scholar]
53. Kozlowska AK, Kaur K, Topchyan P, Jewett A. Novel strategies to target cancer stem cells by NK cells; studies in humanized mice. Front Biosci (Landmark Ed) (2017) 22:370–84. doi: 10.2741/4489 [DOI] [PubMed] [Google Scholar]
54. Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum Immunol (2003) 64(5):505–20. doi: 10.1016/S0198-8859(03)00039-9 [DOI] [PubMed] [Google Scholar]
55. Kaur K, Kozlowska AK, Topchyan P, Ko MW, Ohanian N, Chiang J, et al. Probiotic-treated super-charged NK cells efficiently clear poorly differentiated pancreatic tumors in hu-BLT mice. Cancers (Basel) (2019) 12(1): 63. doi: 10.3390/cancers12010063 [DOI] [PMC free article] [PubMed] [Google Scholar]
56. Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, et al. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer (2017) 8(4):537–54. doi: 10.7150/jca.15989 [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Bui VT, Tseng HC, Kozlowska A, Maung PO, Kaur K, Topchyan P, et al. Augmented IFN-γ and TNF-α induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10. Front Immunol (2015) 6:576. doi: 10.3389/fimmu.2015.00576 [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLos nne (2010) 5(7):e11590. doi: 10.1371/journal.pone.0011590 [DOI] [PMC free article] [PubMed] [Google Scholar]
59. Tseng HC, Cacalano N, Jewett A. Split anergized natural killer cells halt inflammation by inducing stem cell differentiation, resistance to NK cell cytotoxicity and prevention of cytokine and chemokine secretion. Oncotarget (2015) 6(11):8947–59. doi: 10.18632/oncotarget.3250 [DOI] [PMC free article] [PubMed] [Google Scholar]
60. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 169(3):987–98. doi: 10.2353/ajpath.2006.060180 [DOI] [PMC free article] [PubMed] [Google Scholar]
61. Schmiedel BJ, Wende CM, Baessler T, Scheible C, Wirths S, Azuma M, et al. RANKL expressed by acute myeloid leukemia cells impairs NK cell-mediated immune surveillance. Blood (2010) 116(21):2164–4. doi: 10.1182/blood.V116.21.2164.2164 [DOI] [Google Scholar]
62. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest (2007) 117(1):122–32. doi: 10.1172/JCI30074 [DOI] [PMC free article] [PubMed] [Google Scholar]
63. Badros AZ, Meddeb M, Weikel D, Philip S, Milliron T, Lapidus R, et al. Prospective observational study of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma: Microbiota profiling and cytokine expression. Front Oncol (2021) 11:704722. doi: 10.3389/fonc.2021.704722 [DOI] [PMC free article] [PubMed] [Google Scholar]
64. Kitayama J, Atomi Y, Nagawa H, Kuroda A, Mutoh T, Minami M, et al. Functional-analysis of tcr-gamma-delta+ t-cells in tumor-infiltrating lymphocytes (til) of human pancreatic-cancer. Clin Exp Immunol (1993) 93(3):442–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
65. Degrate L, Nobili C, Franciosi C, Caprotti R, Brivio F, Romano F, et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg (2009) 394(1):115–21. doi: 10.1007/s00423-008-0393-4 [DOI] [PubMed] [Google Scholar]
66. Kaur K, Topchyan P, Kozlowska AK, Ohanian N, Chiang J, Maung PO, et al. Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs. Oncoimmunology (2018) 7(5):e1426518. doi: 10.1080/2162402X.2018.1426518 [DOI] [PMC free article] [PubMed] [Google Scholar]
67. Kaur K, Cook J, Park SH, Topchyan P, Kozlowska A, Ohanian N, et al. Novel strategy to expand super-charged NK cells with significant potential to lyse and differentiate cancer stem cells: Differences in NK expansion and function between healthy and cancer patients. Front Immunol (2017) 8:297. doi: 10.3389/fimmu.2017.00297 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file.^{(6.3MB, docx)}

Data Availability Statement

The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding authors.

[B1] 1. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci (2007) 1117:209–57. doi: 10.1196/annals.1402.089 [DOI] [PubMed] [Google Scholar]

[B2] 2. Park S, Kanayama K, Kaur K, Tseng HC, Banankhah S, Quje DT, et al. Osteonecrosis of the jaw developed in mice: Disease variants regulated by gammadelta T cells in oral mucosal barrier immunity. J Biol Chem (2015) 290(28):17349–66. doi: 10.1074/jbc.M115.652305 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B3] 3. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol (2007) 4(1):42–55. doi: 10.1038/ncponc0688 [DOI] [PubMed] [Google Scholar]

[B4] 4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol (2005) 23(34):8580–7. doi: 10.1200/JCO.2005.02.8670 [DOI] [PubMed] [Google Scholar]

[B5] 5. Dehari H, Tomihara K, Ueda M, Shimanishi M, Ono M, Sasaki T, et al. [Clinical investigation of bisphosphonate-related osteonecrosis of the jaws]. Gan To Kagaku Ryoho (2009) 36(13):2587–92. [PubMed] [Google Scholar]

[B6] 6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg (2003) 61(9):1115–7. doi: 10.1016/S0278-2391(03)00720-1 [DOI] [PubMed] [Google Scholar]

[B7] 7. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg (2003) 61(9):1104–7. doi: 10.1016/S0278-2391(03)00328-8 [DOI] [PubMed] [Google Scholar]

[B8] 8. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg (2004) 62(5):527–34. doi: 10.1016/j.joms.2004.02.004 [DOI] [PubMed] [Google Scholar]

[B9] 9. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2012) 23(5):1341–7. doi: 10.1093/annonc/mdr435 [DOI] [PubMed] [Google Scholar]

[B10] 10. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg (2012) 41(11):1397–403. doi: 10.1016/j.ijom.2012.06.020 [DOI] [PubMed] [Google Scholar]

[B11] 11. Thumbigere-Math V, Michalowicz BS, Hodges JS, Tsai ML, Swenson KK, Rockwell L, et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol (2014) 85(2):226–33. doi: 10.1902/jop.2013.130017 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B12] 12. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol (2009) 27(32):5356–62. doi: 10.1200/JCO.2009.21.9584 [DOI] [PubMed] [Google Scholar]

[B13] 13. Cortes-Vieyra R, Rosales C, Uribe-Querol E. Neutrophil functions in periodontal homeostasis. J Immunol Res (2016) 2016:1396106. doi: 10.1155/2016/1396106 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B14] 14. Silva N, Dutzan N, Hernandez M, Dezerega A, Rivera O, Aguillon JC, et al. Characterization of progressive periodontal lesions in chronic periodontitis patients: levels of chemokines, cytokines, matrix metalloproteinase-13, periodontal pathogens and inflammatory cells. J Clin Periodontol (2008) 35(3):206–14. doi: 10.1111/j.1600-051X.2007.01190.x [DOI] [PubMed] [Google Scholar]

[B15] 15. Cheng WC, Hughes FJ, Taams LS. The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol (2014) 41(6):541–9. doi: 10.1111/jcpe.12238 [DOI] [PubMed] [Google Scholar]

[B16] 16. Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, Dutzan N, et al. Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med (2014) 6(229):229ra40. doi: 10.1126/scitranslmed.3007696 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B17] 17. Chambers TJ, Fuller K, McSheehy PM, Pringle JA. The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol (1985) 145(4):297–305. doi: 10.1002/path.1711450403 [DOI] [PubMed] [Google Scholar]

[B18] 18. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev (1992) 13(1):66–80. doi: 10.1210/edrv-13-1-66 [DOI] [PubMed] [Google Scholar]

[B19] 19. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 2(4):389–406. doi: 10.1016/S1534-5807(02)00157-0 [DOI] [PubMed] [Google Scholar]

[B20] 20. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 473(2):139–46. doi: 10.1016/j.abb.2008.03.018 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B21] 21. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 1(1):27–39. [PubMed] [Google Scholar]

[B22] 22. Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int (1998) 63(3):230–5. doi: 10.1007/s002239900519 [DOI] [PubMed] [Google Scholar]

[B23] 23. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int (1991) 49(6):407–15. doi: 10.1007/BF02555852 [DOI] [PubMed] [Google Scholar]

[B24] 24. Piper K, Boyde A, Jones SJ. The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number. Calcif Tissue Int (1994) 54(1):56–61. doi: 10.1007/BF00316291 [DOI] [PubMed] [Google Scholar]

[B25] 25. Hiroi-Furuya E, Kameda T, Hiura K, Mano H, Miyazawa K, Nakamaru Y, et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int (1999) 64(3):219–23. doi: 10.1007/s002239900606 [DOI] [PubMed] [Google Scholar]

[B26] 26. Lerner UH, Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro . Bone (1987) 8(3):179–89. doi: 10.1016/8756-3282(87)90018-4 [DOI] [PubMed] [Google Scholar]

[B27] 27. Ito M, Amizuka N, Nakajima T, Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone (1999) 25(4):447–52. doi: 10.1016/S8756-3282(99)00197-0 [DOI] [PubMed] [Google Scholar]

[B28] 28. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, et al. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res (1998) 13(11):1721–9. doi: 10.1359/jbmr.1998.13.11.1721 [DOI] [PubMed] [Google Scholar]

[B29] 29. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo . J Bone Miner Res (1995) 10(10):1478–87. doi: 10.1002/jbmr.5650101008 [DOI] [PubMed] [Google Scholar]

[B30] 30. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol (1996) 50(5):1127–38. [PubMed] [Google Scholar]

[B31] 31. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: Mechanism of action and clinical outcomes. Int J Clin Pract (2012) 66(12):1139–46. doi: 10.1111/ijcp.12022 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B32] 32. Fildes JE, Yonan N, Leonard CT. Natural killer cells and lung transplantation, roles in rejection, infection, and tolerance. Transpl Immunol (2008) 19(1):1–11. doi: 10.1016/j.trim.2008.01.004 [DOI] [PubMed] [Google Scholar]

[B33] 33. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev (2006) 20(3):123–37. doi: 10.1016/j.blre.2005.10.001 [DOI] [PubMed] [Google Scholar]

[B34] 34. Soderstrom K, Stein E, Colmenero P, Purath U, Muller-Ladner U, de Matos CT, et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci United States America (2010) 107(29):13028–33. doi: 10.1073/pnas.1000546107 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B35] 35. Delves PJ, Roitt IM. The immune system. second of two parts. N Engl J Med (2000) 343(2):108–17. doi: 10.1056/NEJM200007133430207 [DOI] [PubMed] [Google Scholar]

[B36] 36. Popoff SN, Jackson ME, Koevary SB, Marks SC, Jr. Coexistence of reduced function of natural killer cells and osteoclasts in two distinct osteopetrotic mutations in the rat. J Bone Miner Res (1991) 6(3):263–71. doi: 10.1002/jbmr.5650060308 [DOI] [PubMed] [Google Scholar]

[B37] 37. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood (2010) 116(2):210–7. doi: 10.1182/blood-2009-11-255026 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B38] 38. Tseng HC, Kanayama K, Kaur K, Park SH, Park S, Kozlowska A, et al. Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget (2015) 6(24):20002–25. doi: 10.18632/oncotarget.4755 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B39] 39. Kozlowska AK, Kaur K, Topchyan P, Jewett A. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice. Cancer Immunol Immunother (2016) 65(7):835–45. doi: 10.1007/s00262-016-1822-9 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B40] 40. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res (2007) 22(10):1479–91. doi: 10.1359/jbmr.0707onj [DOI] [PubMed] [Google Scholar]

[B41] 41. Allen MR, Ruggiero SL. Osteonecrosis of the jaw: Recent clinical and preclinical advances. IBMS BoneKEy (2011) 8(3):141–53. doi: 10.1138/20110500 [DOI] [Google Scholar]

[B42] 42. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 172(5):2731–8. doi: 10.4049/jimmunol.172.5.2731 [DOI] [PubMed] [Google Scholar]

[B43] 43. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U.S.A. (2013) 110(9):3507–12. doi: 10.1073/pnas.1222878110 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B44] 44. Tao L, Reese TA. Making mouse models that reflect human immune responses. Trends Immunol (2017) 38(3):181–93. doi: 10.1016/j.it.2016.12.007 [DOI] [PubMed] [Google Scholar]

[B45] 45. Stoddart CA, Maidji E, Galkina SA, Kosikova G, Rivera JM, Moreno ME, et al. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. Virology (2011) 417(1):154–60. doi: 10.1016/j.virol.2011.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B46] 46. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 12(11):786–98. doi: 10.1038/nri3311 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B47] 47. Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2010) 115(8):1534–44. doi: 10.1182/blood-2009-04-215855 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B48] 48. Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, et al. Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J Vis Exp (2012) 70):e4181. doi: 10.3791/4181 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B49] 49. Park S, Kanayama K, Kaur K, Tseng HC, Banankhah S, Quje DT, et al. Osteonecrosis of the jaw developed in mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY. J Biol Chem (2015) 290(28):17349–66. doi: 10.1074/jbc.M115.652305 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B50] 50. Sun Y, Kaur K, Kanayama K, Morinaga K, Park S, Hokugo A, et al. Plasticity of myeloid cells during oral barrier wound healing and the development of bisphosphonate-related osteonecrosis of the jaw. J Biol Chem (2016) 291(39):20602–16. doi: 10.1074/jbc.M116.735795 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B51] 51. Kaur K, Kanayama K, Wu QQ, Gumrukcu S, Nishimura I, Jewett A. Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2(-/-) mice; stark differences between the bone marrow and gingivae. Cell Immunol (2022) 375:104526. doi: 10.1016/j.cellimm.2022.104526 [DOI] [PubMed] [Google Scholar]

[B52] 52. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U.S.A. (2011) 108(51):E1408–16. doi: 10.1073/pnas.1115050108 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B53] 53. Kozlowska AK, Kaur K, Topchyan P, Jewett A. Novel strategies to target cancer stem cells by NK cells; studies in humanized mice. Front Biosci (Landmark Ed) (2017) 22:370–84. doi: 10.2741/4489 [DOI] [PubMed] [Google Scholar]

[B54] 54. Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum Immunol (2003) 64(5):505–20. doi: 10.1016/S0198-8859(03)00039-9 [DOI] [PubMed] [Google Scholar]

[B55] 55. Kaur K, Kozlowska AK, Topchyan P, Ko MW, Ohanian N, Chiang J, et al. Probiotic-treated super-charged NK cells efficiently clear poorly differentiated pancreatic tumors in hu-BLT mice. Cancers (Basel) (2019) 12(1): 63. doi: 10.3390/cancers12010063 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B56] 56. Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, et al. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer (2017) 8(4):537–54. doi: 10.7150/jca.15989 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B57] 57. Bui VT, Tseng HC, Kozlowska A, Maung PO, Kaur K, Topchyan P, et al. Augmented IFN-γ and TNF-α induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10. Front Immunol (2015) 6:576. doi: 10.3389/fimmu.2015.00576 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B58] 58. Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLos nne (2010) 5(7):e11590. doi: 10.1371/journal.pone.0011590 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B59] 59. Tseng HC, Cacalano N, Jewett A. Split anergized natural killer cells halt inflammation by inducing stem cell differentiation, resistance to NK cell cytotoxicity and prevention of cytokine and chemokine secretion. Oncotarget (2015) 6(11):8947–59. doi: 10.18632/oncotarget.3250 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B60] 60. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 169(3):987–98. doi: 10.2353/ajpath.2006.060180 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B61] 61. Schmiedel BJ, Wende CM, Baessler T, Scheible C, Wirths S, Azuma M, et al. RANKL expressed by acute myeloid leukemia cells impairs NK cell-mediated immune surveillance. Blood (2010) 116(21):2164–4. doi: 10.1182/blood.V116.21.2164.2164 [DOI] [Google Scholar]

[B62] 62. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest (2007) 117(1):122–32. doi: 10.1172/JCI30074 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B63] 63. Badros AZ, Meddeb M, Weikel D, Philip S, Milliron T, Lapidus R, et al. Prospective observational study of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma: Microbiota profiling and cytokine expression. Front Oncol (2021) 11:704722. doi: 10.3389/fonc.2021.704722 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B64] 64. Kitayama J, Atomi Y, Nagawa H, Kuroda A, Mutoh T, Minami M, et al. Functional-analysis of tcr-gamma-delta+ t-cells in tumor-infiltrating lymphocytes (til) of human pancreatic-cancer. Clin Exp Immunol (1993) 93(3):442–7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B65] 65. Degrate L, Nobili C, Franciosi C, Caprotti R, Brivio F, Romano F, et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg (2009) 394(1):115–21. doi: 10.1007/s00423-008-0393-4 [DOI] [PubMed] [Google Scholar]

[B66] 66. Kaur K, Topchyan P, Kozlowska AK, Ohanian N, Chiang J, Maung PO, et al. Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs. Oncoimmunology (2018) 7(5):e1426518. doi: 10.1080/2162402X.2018.1426518 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B67] 67. Kaur K, Cook J, Park SH, Topchyan P, Kozlowska A, Ohanian N, et al. Novel strategy to expand super-charged NK cells with significant potential to lyse and differentiate cancer stem cells: Differences in NK expansion and function between healthy and cancer patients. Front Immunol (2017) 8:297. doi: 10.3389/fimmu.2017.00297 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ

Kawaljit Kaur

Yujie Sun

Keiichi Kanayama

Kenzo Morinaga

Akishige Hokugo

Ichiro Nishimura

Anahid Jewett

Abstract

Introduction

Methods

Results

Discussion

Introduction

Materials and methods

Ethics statement

ZOL or denosumab injection and molar tooth extraction in mice

Human immune cells isolation and generation of human osteoclasts

Mice tissue preparation, and culture of single cell suspension

Surface markers analysis

Enzyme-linked immunosorbent assays and multiplex cytokine assay

51Cr release cytotoxicity assay

Antibody-dependent cell-mediated cytotoxicity measurements

Statistical analysis

Results

Differential proportions of immune cells in peripheral blood of WT mice compared to either hu-BLT mice or humans

Figure 1.

ZOL-mediated effect on IFN-γ secretion and NK cell-mediated cytotoxicity in hu-BLT mice

Figure 2.

Table 1.

Table 2.

Injection of ZOL decreased IFN-γ secretion but increased NK cell-mediated cytotoxicity in tooth extracted oral gingival tissue of hu-BLT mice

Figure 3.

Table 3.

Table 4.

Effect of ZOL injection on IFN-γ secretion and key immune cells in PBMCs, BM, spleen and pancreas of tooth-extracted hu-BLT mice

Figure 4.

Table 5.

Effect of ZOL injection on NK cell-mediated cytotoxicity in PBMCs, BM, spleen and pancreas of tooth-extracted hu-BLT mice

Figure 5.

Denosumab-mediated effect in IFN-γ secretion and NK cell-mediated cytotoxicity in hu-BLT mice

Figure 6.

Higher levels of NK cell-mediated ADCC were seen against OCs treated with a combination of denosumab and RANKL

Figure 7.

Discussion

Data availability statement

Ethics statement

Author contributions

Conflict of interest

Publisher’s note

Supplementary material

References

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

⁵¹Cr release cytotoxicity assay